Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Filamon LTD
Ensem Therapeutics
Atavistik Bio, Inc
Eisai Inc.
Fondazione del Piemonte per l'Oncologia
PMV Pharmaceuticals, Inc
AstraZeneca
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
NeoImmuneTech
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Rutgers, The State University of New Jersey
AstraZeneca
BeOne Medicines
National Institutes of Health Clinical Center (CC)
Aveni Foundation
University of California, Davis
Bayer
Genmab
Genmab
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
Eli Lilly and Company
ViroMissile, Inc.
EMD Serono
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Dana-Farber Cancer Institute
University of Miami
Genmab
Jazz Pharmaceuticals
Kaiser Permanente
Accent Therapeutics
Carevive Systems, Inc.
Duke University